VivoSeq
Other

Hepatic Insufficiency

0

Pipeline Programs↗

1

Active Trials↗

9

Companies Involved↗

Hepatic Insufficiency is an early-stage landscape with 0 programs across 9 companies. The most active players are Boehringer Ingelheim, Merck & Co., Ahon Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalA

Ahon Pharmaceutical Co., Ltd.

0 programs

PreclinicalN

Neurodawn Pharmaceutical Co., Ltd.

0 programs

PreclinicalA

Acerta Pharma BV

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Completed18 · 75%
Unknown status4 · 17%
Not yet recruiting1 · 4%
Terminated1 · 4%

Clinical Trials

Trial Activity

24 trials

Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
Not yet recruiting·NNeurodawn Pharmaceutical Co., Ltd.·Phase 1·NCT07055412·24 enrolled
Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01043926·16 enrolled
Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01114490·24 enrolled
Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01390428·50 enrolled
A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196
Completed·AAcerta Pharma BV·Phase 1·NCT04867941·18 enrolled
Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01043887·19 enrolled
A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00696826·20 enrolled
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
Completed·Ipsen logoIpsen·Phase 1·NCT02683577·24 enrolled
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02666352·24 enrolled
The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01797536·31 enrolled
A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01010906·60 enrolled
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
Completed·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 1·NCT01916993·24 enrolled
A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02089659·16 enrolled
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
Completed·Novartis logoNovartis·Phase 1·NCT00968591·34 enrolled
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
Completed·NNanjing Zenshine Pharmaceuticals·Phase 1·NCT05711797·16 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)